Operates two service lines for pharmaceutical clients: Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). The CDMO business generated ₹1,417 crore in FY26, up 33% year-on-year, while the CRO business generated ₹775 crore, up 24% year-on-year. Together they delivered ₹2,192.49 crore in revenue for FY26, a 29% rise over the prior year. EBITDA reached ₹661 crore at a 30.66% margin, with net profit of ₹348.91 crore. A front-loaded capex of ₹1,100-1,300 crore is planned for FY27 — versus ₹633 crore in FY26 — with 62% allocated to CDMO and 38% to CRO/capabilities, aimed at nearly doubling manufacturing capacity by FY27. The largest cost lines are employees at 31.2% of revenue and materials at 26.4%, followed by other operating expenses (14%) and depreciation (7.6%). Middle East geopolitical tensions have raised input and logistics costs, prompting customer discussions on cost revisions. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. CDMO (Contract Development and Manufacturing Organization), CRO (Contract Research Organization). Service-driven pharma outsourcing with high employee intensity and front-loaded capex
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 1,695 | 2,192 |
| EBITDA (ex other income) | 406 | 623 |
| margin % | 23.9 | 28.4 |
| Owners' profit | 170 | 349 |
| EPS, as reported (₹) | 8.83 | 16.63 |
| ROE % · ROCE % | 8.0 · 12.5 | 14.0 · 18.1 |
| Debt / equity (x) | 0.06 | 0.04 |
| Cash from operations | 314 | 509 |
| Capex | (369) | (593) |
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Profit before tax | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Net profit | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS (₹) | 2.89 | 4.24 | 2.90 | 4.01 | 4.77 | 4.93 | 3.46 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Sai Life Sciences to attend Jefferies 5th India Forum on Sept 18 | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Sai Life Sciences to attend Morgan Stanley Healthcare Conference on Sep 14 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Allotment of 80,600 shares under ESOP plans | capital market events | low | — | — |
| 26 Aug 2026 · Newspaper publication of 27th AGM notice by Sai Life Sciences | compliance | minimal | — | — |
| 25 Aug 2026 · Sai Life Sciences sends weblink letter for FY26 annual report and 27th AGM | compliance | minimal | — | — |
| 25 Aug 2026 · Sai Life Sciences files BRSR and ESG Databook for FY 2025-26 | compliance | medium | — | — |
| 25 Aug 2026 · FY2025-26 report shows 29% revenue growth and 105% PAT growth | investor communications | medium | — | — |
| 25 Aug 2026 · Sai Life Sciences 27th AGM on Sept 17, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Sai Life Sciences announces 27th AGM on September 17, 2026 | compliance | minimal | — | — |
| 24 Aug 2026 · 27th AGM on Sept 17, 2026; e-voting cut-off Sept 10 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 92.3 | 28.9 | 152 of 169 | 10% |
| P/B | 13.6 | 3.3 | 150 of 163 | 8% |
| ROCE | 16.7 | 10.8 | 50 of 183 | 73% |
| ROE | 14.1 | 10.4 | 54 of 171 | 69% |
| Debt / Equity | 0.0 | 0.1 | 63 of 171 | 64% |
| EBITDA margin | 27.3 | 17.5 | 43 of 165 | 74% |
| Revenue growth | 11.7 | 16.3 | 89 of 161 | 45% |
| Profit growth | 21.2 | 30.9 | 88 of 158 | 45% |
| Market cap | 33648 | 839 | 21 of 182 | 89% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
